1 / 31

Lenalidomide

Lenalidomide. Lenalidomide in transfusion dependant del 5q MDS. O. O. O. O. H. H. N. N. N. O. N. O. N. H. O. 2. Lenalidomide: pharmacological evolution. More “potent” immunomodulator than thalidomide up to 50,000 times more potent inhibitor of TNF- 

chavi
Télécharger la présentation

Lenalidomide

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Lenalidomide Lenalidomide in transfusion dependant del 5q MDS

  2. O O O O H H N N N O N O N H O 2 Lenalidomide:pharmacological evolution More “potent” immunomodulator than thalidomide • up to 50,000 times more potent inhibitor of TNF- • increased stimulation of T-cell proliferation • augmented stimulation of IL-2 and IFN- production • augmented NK-cell activity Thalidomide Lenalidomide Bartlett JB, et al. Nat Rev Cancer. 2004;4:314-22. Davies FE, et al. Blood. 2001;98:210-6. Stirling D. Semin Oncol. 2001;28:602-6.

  3. Clinical development of lenalidomide in MDS: completed trials MDS-001 N = 43 Phase I/II initiated Feb 2002 del(5q) non-del(5q) MDS-003 N = 148 Phase II initiated July 2003 MDS-002 N = 214 Phase II initiated July 2003

  4. MDS-003: study design Multi-centre phase II study R E G I S T E R R E S P O N S E • Eligibility • RBC transfusion  2 U/8 weeks • 16-week pre-study RBC transfusions • ANC > 0.5 × 109/l • Platelets > 50 × 109/l • De novo MDS withdel(5)(q31.1) Yes Continue • Lenalidomide, p.o. • 10 mg daily • 10 mg for 21 days of each 28-day cycle No Off study Dose reduction 5 mg every day. 5 mg every other day. Week: 0 6 12 18 24 Primary end-point: transfusion independence (Hb  ≥ 1 g/dl) Secondary end-points: duration of transfusion independence, frequency of minor erythroid response, cytogenetic response, pathological response, safety List A, et al. N Engl J Med. 2006;355:1456-65.

  5. MDS-003: patientcharacteristics List A, et al. N Engl J Med. 2006;355:1456-65.

  6. MDS-003: cytogenetic features *4 normal metaphases analysed; 85% of 100 interphase nuclei lacked EGR1 signal at 5q31. Data from List A, et al. N Engl J Med. 2006;355:1456-65.

  7. MDS-003: erythroid response at 24 weeks (ITT) *p< 0.001 No significant difference in erythroid response or time to response between the 2 dosing regimens. Data from List A, et al. N Engl J Med. 2006;355:1456-65.

  8. MDS-003: durability of transfusion independence responses • For the 99 del(5q) RBC-TI responders in MDS-003, estimated median duration of response is 115 weeks • 52 (53%) remain on study with ongoing transfusion independence (June 30, 2006) • > 52 weeks for 63 patients • > 78 weeks for 52 patients • > 104 weeks for 36 patients • RBC-TI and major erythroid response to lenalidomide is maintained for a median duration of > 2 years List AF, et al. Presented at ASH Annual Meeting, 2006 [abstract 251].

  9. MDS-003: transfusion-independence rate by cytogenetic pattern *p = 0.068. #Excluding 1 patient whose cytogenetic characteristics were defined by FISH only. Data from List A, et al. N Engl J Med. 2006;355:1456-65.

  10. MDS-003: cytogenetic response by karyotype complexity *p = 0.266. Data from List A, et al. N Engl J Med. 2006;355:1456-65.

  11. MDS-003: pathological response In 106 evaluable patients Data from List A, et al. N Engl J Med. 2006;355:1456-65.

  12. MDS-003: anti-angiogenesisin vivo in del(5q) MDS Markers of angiogenesis in bone marrow biopsies/aspirates from 35 patients with del(5q) MDS: at baseline and 6 and 12 months after start of lenalidomide therapy *Patients with normal bone marrow (n = 20). # Increases were significant (p = 0.0005) but independent of cytogenetic response. Anti-angiogenic inefficacy of lenalidomide in 14/35 patients correlated with disease progression (≥ 5% blasts in blood or bone marrow; p = 0.0005). Data from Buesche G, et al. Blood. 2005;106:113a [abstract 372].

  13. Disease progression in del(5q) MDS patients treated with lenalidomide Retrospective subanalysis of MDS-003 (n = 45) Lenalidomide does not appear to lead to an excess rate of transformation to acute myeloid leukaemia Giagounidis A, et al. Poster presented at EHA Congress, 2007 [abstract 234].

  14. Cytopenias correlate with response to lenalidomide in del(5q) MDS patients Retrospective analysis of MDS-003 study • Baseline characteristics (147 evaluable patients) • neutropenia (< 2.0 × 109/l) 59 (40%) • thrombocytopenia (< 150 × 109/l) 59 (40%) • neutropenia or thrombocytopenia 84 (57%) • Treatment-related neutropenia: ANC reduction ≥ 75% • Treatment-related thrombocytopenia: platelet count reduction ≥ 50% Sekeres MA, et al. Leuk Res. 2007;31 (Suppl 1) [abstract C027].

  15. Multivariate analysis: factors associated with duration of transfusion independence Sekeres MA, et al. Haematologica. 2007;92 (Suppl 1) [abstract 230].

  16. MDS-003:treatment-related adverse events List A, et al. N Engl J Med. 2006;355:1456-65.

  17. MDS-003: dose adjustments according to schedule N = 148 102 *p < 0.05 Patients (n) 46 List A, et al. N Engl J Med. 2006;355:1456-65.

  18. MDS-003: drug discontinuation according to schedule N = 148 102 *p < 0.05 Patients (n) 46 List A, et al. N Engl J Med. 2006;355:1456-65.

  19. MDS-003: medical reason for drug discontinuation in 30 patients • Neutropenia and thrombocytopenia (n = 10) • Rash (n = 5) • AML (n = 3) • n = 1: anaemia, facial oedema, chronic heart failure, urticaria, diarrhoea, weight loss, renal insufficiency, CVA, dementia, dyspnea, pyrexia, pneumonia List A, et al. N Engl J Med. 2006;355:1456-65.

  20. Haematological adverse events in MDS: management recommendations (1) • Monitor FBC weekly for a mandatory 8 weeks • weekly FBC monitoring may be continued for up to 5 months • consider continued biweekly or monthly monitoring on the basis of haematological status • ANC < 1 × 109/l: co-administration of G-CSF is recommended to prevent severe neutropenia • alternatively, lenalidomide treatment can be temporarily discontinued • ANC < 0.5 × 109/l ,interrupt lenalidomide treatment, this can be reintroduced if ANC ≥ 0.75 × 109/l after one week. • Neutropenic sepsis is the only reported drug-related cause of death. Patients should • receive education • receive prophylactic antibiotics at neutrophil counts < 0.5 × 109/l • have all-day access to specialized haematological care • receive broad spectrum antibiotics within 3 hours of fever onset Giagounidis A, et al. Presented at EHA Congress, 2007 [abstract 227].

  21. Haematological adverse events in MDS: management recommendations (2) • If platelet count falls to < 25 × 109/l without platelet support, lenalidomide treatment should be interrupted • thrombocytopenia at baseline is not a contraindication for lenalidomide treatment • consider prophylactic platelet transfusions until counts rise • If, after ≥ 1 week discontinuation, the platelet count is ≥ 50 × 109/l, lenalidomide can be reintroduced Giagounidis A, et al. Presented at EHA Congress, 2007 [abstract 227].

  22. VTE in MDS: management recommendations • VTE is a rare event in lenalidomide-treated MDS (3%)1,2 • VTE prophylaxis is not generally recommended • Patients should be informed about the risk of VTE and monitored for symptoms • Combined lenalidomide and erythropoietin treatment is currently not recommended outside a clinical trial • may increase risk of venous thromboembolism3 • If VTE does occur, interrupt the lenalidomide treatment, treat the VTE, and carefully reintroduce lenalidomide once stable anticoagulation has been established • There is currently no consensus on the role of aspirin or LMWH use3 1. List A, et al. N Engl J Med. 2005;352:549-57. 2. List A, et al. N Engl J Med. 2006;355:1456-65. 3. Giagounidis A, et al. Presented at EHA Congress, 2007 [abstract 227].

  23. Non-haematological adverse events: management recommendations (1) • Most non-haematological adverse events are self-limiting and do not require discontinuation of lenalidomide • Rash • usually resolves within 2–3 weeks • may be treated, if necessary, with unselective antihistamines, topical steroids, or short-course prednisone (10 mg, 14 days) • if rash is severe or persistent despite treatment, lenalidomide treatment should be interrupted until rash resolves • usually does not recur after resolution and resumption of lenalidomide treatment at lower dose level • Diarrhoea • treat symptomatically after ruling out other underlying causes • Fatigue is not considered drug-related Giagounidis A, et al. Presented at EHA Congress, 2007 [abstract 229].

  24. Non-haematological adverse events: management recommendations (2) • Hypothyroidism • screen for thyroid-stimulating hormone triiodothyronine (T3) and thyroxine (T4) and monitor during the course of treatment • in case of hypothyroidism, thyroid hormone replacement therapy may be needed • Other non-haematological adverse events • treat symptomatically after ruling out other underlying causes such as anaemia or autoimmune disorders Giagounidis A, et al. Presented at EHA Congress, 2007 [abstract 229].

  25. Interactions • Lenalidomide is not metabolised through cytochrome P450 pathway and therefore low potential for metabolic interactions • Lenalidomide-warfarin interaction study did not indicate any interaction. However dexamethasone is a weak to moderate enzyme inducer. Close monitoring of warfarin therapy is thereofre recommended. • Lenalidomide –digoxin interaction study showed minor changes in relevent parameters suggesting potential for minor interaction. • Monitoring of digoxin plasma levels is recommended during administration of lenalidomide

  26. Use in patients with impaired hepatic or renal function • Impaired hepatic function • Lenalidomide has not formally been studied in patients with impaired hepatic function and there are no specific dose recommendations • Impaired renal function • Lenalidomide is substantially excreted by the kidney • Care should be taken in dose selection and monitoring of renal function is advised • Dose reductions are recommended at the start of therapy for patients with impaired renal function

  27. Dose initiation in patients with renal failure

  28. Prevention of fœtal exposure • Lenalidomide is structurally related to thalidomide. Currently a teratogenic effect of lenalidomide cannot be ruled out. • Lenalidomide is contraindicated • In pregnancy • In Women of Childbearing Potential (WCBP) unless all the conditions of the Pregnancy Prevention Programme are met

  29. Prevention of fœtal exposure • All patients: • Do not share medication • Do not donate blood during treatment or for one week after cessation of treatment • Male patients • Potential teratogenic risk • Use of condoms during sexual contact with WCBP even if prior vasectomy. • Female partner must consult physician if she becomes pregnant whilst partner on treatment • WCBP (refer to Information Pack for further information) • Potential teratogenic risk • Effective contraception 4 weeks before treatment, during treatment, during dose interruptions and 4 weeks after end of treatment • Negative pregnancy test before treatment and at specific intervals. • If becomes pregnant to stop treatment and consult physician

  30. Adverse Event/Suspected Pregnancy Reporting • Adverse Event: • Any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.

  31. Adverse Event/Suspected Pregnancy Reporting • Report immediately • All Adverse events • Serious and non serious • Regardless of expectedness • All reports of suspected pregnancies • Report by telephone: NEOPHARM Shavit Fragman, Telephone No. : 03-9373753/65 Mobile No. : 054-6777865 Mrs. Ayala Weissman, Telephone No. : 03-9373753 Mobile No. : 052-8696199 Mrs. Keren Moreno, Telephone No. : 03-9373753/0 Mobile No. : 052-8777971

More Related